2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC.
1 across the spectrum. Choose a side on the bar to jump to it.
2 articles from 1 source. Updated 7d ago.
Left
0 sourcesNo Left coverage yet.
A blind spot on this side of the story.
Center
1 source2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
Right
0 sourcesNo Right coverage yet.
A blind spot on this side of the story.